[Laboratory and clinical studies on cefsulodin (author's transl)].
Laboratory and clinical studies on cefsulodin (CFS), a new antipseudomonal cephalosporin antibiotic, were carried out and the following results were obtained. 1. The MIC of CFS against P. aeruginosa showed the peak of susceptibility at 3.13 mcg/ml in the inoculum size of 10(8) cells/ml and at 1.56 mcg/ml in the inoculum size of 10(8) cells/ml. It has a higher superiority as compared with gentamicin or piperacillin and gentamicin-resistant strains of P. aeruginosa were sensitive to CFS. 2. CFS was given to 3 patients with acute pneumonia and 5 patients with chronic cystitis which were all due to P. aeruginosa. Clinical effects were good in 2 patients and poor in a patient with acute pneumonia, and those were good in 3 patients and poor in 2 patients with chronic cystitis. Side effects were not recognized at all.
D000328:Adult; D000368:Aged; D002441:Cefsulodin; D002511:Cephalosporins / Q000494:pharmacology* / Q000627:therapeutic use; D003556:Cystitis / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D005839:Gentamicins / Q000494:pharmacology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010403:Penicillin Resistance; D010406:Penicillins / Q000494:pharmacology; D010878:Piperacillin; D011014:Pneumonia / Q000188:drug therapy*; D011552:Pseudomonas Infections / Q000188:drug therapy*; D011550:Pseudomonas aeruginosa / Q000187:drug effects*
D002511:Cephalosporins; D005839:Gentamicins; D010406:Penicillins; D002441:Cefsulodin; D010878:Piperacillin